Heat Biologics Announces Additional Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients at AACR Tumor Immunology and Immunotherapy Conference Nov 18, 2019
Heat Biologics Presents Additional Phase 2 Interim Data in Advanced NSCLC Patients at the SITC 34th Annual Meeting Nov 11, 2019
Heat Biologics Reports Positive Phase 2 Interim Data in NSCLC Patients Who Previously Failed Checkpoint Inhibitor Treatment Nov 5, 2019
Heat Biologics Announces a Poster Presentation of Updated Top Line Phase 2 Data of HS-110 plus Nivolumab after Checkpoint Inhibitor Treatment Failure in NSCLC Patients at the SITC 34th Annual Meeting Oct 24, 2019
Heat Biologics Announces FDA Clearance of IND Application to Begin Phase 1 Trial of HS-130 in Combination with Heat’s HS-110 Aug 12, 2019
Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure Jun 3, 2019
